BGM
AVBP icon

Burkehill Global Management’s ArriVent BioPharma AVBP Stock Holding History

Burkehill Global Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.31M Hold
100,000
– – 0.11% 117
2025
Q4 		$2.01M Hold
100,000
– – 0.13% 119
2025
Q3 		$1.84M Buy
+100,000
New +$1.96M 0.1% 123

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Burkehill Global Management's AVBP Position: Q1 2026 in Review

Burkehill Global Management held its ArriVent BioPharma (AVBP) position steady in Q1 2026 at 100,000 shares worth $2.31M. The position accounts for 0.11% of the portfolio, ranked #117.

Burkehill Global Management first reported a position in AVBP in Q3 2025 and has held it in 3 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Burkehill Global Management held 100,000 shares of ArriVent BioPharma worth $2.31M as of Q1 2026.
  • Burkehill Global Management left its ArriVent BioPharma share count unchanged in Q1 2026.
  • ArriVent BioPharma made up 0.11% of Burkehill Global Management's portfolio in Q1 2026, its #117 holding.
  • Burkehill Global Management first reported a position in ArriVent BioPharma in Q3 2025 and has held it in 3 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Burkehill Global Management's 13F filing for Q1 2026, filed 15 May 2026.